论文部分内容阅读
摘要目的探讨全身扩散加权成像(DWI)评估转移性去势抵抗前列腺癌(m CRPC)病人骨转移治疗后反应的有效性。材料与方法 m CRPC的多聚-(腺苷二磷酸-核糖)聚合酶抑制剂奥拉帕尼的Ⅱ期前瞻性临床试验中包括前瞻性MR成像的分项研究;这项研究由机构伦理委员会批准,并获得书面知情同意书。于基线和使用奥拉帕尼12周后,在1.5 T MR上进行全身DWI检查。描绘出与骨转移部位一致的DWI影像异常信号强度区域,计算总扩散体积(t DV);并对5个靶
Abstract Objective To investigate the effectiveness of diffusion-weighted imaging (DWI) in evaluating response to bone metastases in patients with metastatic potential prostate cancer (mCRPC). Materials and Methods m CRPC poly- (adenosine diphosphate-ribose) polymerase inhibitor Phase II prospective Olaparib clinical trials included prospective MR imaging of a sub-study that was conducted by the Institutional Ethics Committee Approve and obtain written informed consent. After 12 weeks of baseline and Olaparib use, a total body DWI was performed on the 1.5 T MR. The area of abnormal signal intensity of DWI images consistent with the site of bone metastasis was plotted to calculate the total diffusion volume (t DV). Five target